tiprankstipranks
Trending News
More News >
Bristol-Myers Squibb (BMY)
NYSE:BMY
US Market
Advertisement

Bristol-Myers Squibb (BMY) Earnings Dates, Call Summary & Reports

Compare
11,810 Followers

Earnings Data

Report Date
Feb 05, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
1.61
Last Year’s EPS
1.67
Same Quarter Last Year
Based on 17 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Oct 30, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in the portfolio, increased revenue guidance, and successful business development activities. However, there remain challenges with the adoption of new products like Cobenfy and the uncertainty surrounding IRA negotiations.
Company Guidance
During the third quarter 2025 earnings call, Bristol-Myers Squibb provided updated guidance reflecting strong performance and strategic execution. The company's growth portfolio saw a 17% year-over-year increase in sales, driven by products such as Reblozyl, Camzyos, and Breyanzi, among others. Consequently, BMS raised its full-year revenue guidance to $47.5 billion to $48 billion, while maintaining its EPS guidance at $6.40 to $6.60. The company highlighted several clinical and regulatory milestones, including positive data from the Phase III EXCALIBER study for Iberdomide and ongoing pivotal studies for pumitamig. In terms of cost management, BMS continues to execute its strategic productivity initiatives, achieving over $1 billion in net savings compared to 2024 levels. The company also emphasized its focus on maintaining financial discipline and investing in its growth portfolio and pipeline to drive future growth.
Strong Growth Portfolio Performance
Sales increased 17% year-over-year, driven by multiple products including IO portfolio, Reblozyl, Camzyos, and Breyanzi. Four products are now annualizing over $1 billion in sales.
Increased Revenue Guidance
Full year revenue guidance raised by $750 million at the midpoint to a range of $47.5 billion to $48 billion.
Positive Clinical and Regulatory Milestones
Several milestones achieved, including breakthrough therapy designation for iza-bren and Fast Track designation for anti-tau antibody.
Business Development Initiatives
Recent acquisition of Orbital Therapeutics and partnership with SystImmune, enhancing the cell therapy franchise and RNA technology platform.
Progress in Cost Management
Operating expenses decreased by approximately $100 million to roughly $4.2 billion compared to the same period last year, achieving significant cost savings.

Bristol-Myers Squibb (BMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BMY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 05, 2026
2025 (Q4)
1.61 / -
1.67
Oct 30, 2025
2025 (Q3)
1.52 / 1.63
1.8-9.44% (-0.17)
Aug 01, 2025
2025 (Q2)
1.09 / 1.46
2.07-29.47% (-0.61)
Apr 24, 2025
2025 (Q1)
1.50 / 1.80
-4.4140.91% (+6.20)
Feb 06, 2025
2024 (Q4)
1.46 / 1.67
1.7-1.76% (-0.03)
Oct 31, 2024
2024 (Q3)
1.49 / 1.80
2-10.00% (-0.20)
Jul 26, 2024
2024 (Q2)
1.62 / 2.07
1.7518.29% (+0.32)
Apr 25, 2024
2024 (Q1)
-4.41 / -4.40
2.05-314.63% (-6.45)
Feb 02, 2024
2023 (Q4)
1.55 / 1.70
1.82-6.59% (-0.12)
Oct 26, 2023
2023 (Q3)
1.76 / 2.00
1.990.50% (+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BMY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 30, 2025
$42.60$45.62+7.09%
Aug 01, 2025
$42.72$43.63+2.13%
Apr 24, 2025
$47.25$47.40+0.32%
Feb 06, 2025
$57.51$55.30-3.84%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bristol-Myers Squibb (BMY) report earnings?
Bristol-Myers Squibb (BMY) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).
    What is Bristol-Myers Squibb (BMY) earnings time?
    Bristol-Myers Squibb (BMY) earnings time is at Feb 05, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BMY EPS forecast?
          BMY EPS forecast for the fiscal quarter 2025 (Q4) is 1.61.

            Bristol-Myers Squibb (BMY) Earnings News

            BMY Earnings: Bristol Myers Squibb Stock Rises on Q2 Beats & Strong 2025 Guidance
            Premium
            Market News
            BMY Earnings: Bristol Myers Squibb Stock Rises on Q2 Beats & Strong 2025 Guidance
            3M ago
            BMY Earnings: Bristol Myers Squibb Posts Strong Q2 Results
            Premium
            Market News
            BMY Earnings: Bristol Myers Squibb Posts Strong Q2 Results
            1y ago
            Bristol-Myers (NYSE:BMY) Rises on Q4 Beat
            Premium
            Market News
            Bristol-Myers (NYSE:BMY) Rises on Q4 Beat
            2y ago
            Bristol-Myers Squibb (NYSE:BMY) Tanks on Q2 Miss; Guidance Disappoints
            Premium
            Market News
            Bristol-Myers Squibb (NYSE:BMY) Tanks on Q2 Miss; Guidance Disappoints
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis